Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–23 of 23 results
Advanced filters: Author: Ziad Massy Clear advanced filters

  • Abundant evidence suggests a physiological role of magnesium in cardiovascular function. As the kidney is a major regulator of magnesium homeostasis, serum magnesium levels and magnesium balance are often altered in patients with chronic kidney disease (CKD). In this article, Ziad Massy and Tilman Drüeke review the findings of experimental and clinical studies that provide evidence for a role of magnesium in the high frequency of cardiovascular disease in patients with CKD.

    • Ziad A. Massy
    • Tilman B. Drüeke
    Reviews
    Nature Reviews Nephrology
    Volume: 11, P: 432-442

  • Arterial calcification is highly prevalent in patients with chronic kidney disease, and is a process associated with cardiovascular morbidity and mortality. Calcium phosphate deposits may be found in the intima, the media, or both. Whether determination of the precise location of calcification is possible and whether this distinction is clinically useful remains a matter of debate.

    • Tilman B. Drüeke
    • Ziad A. Massy
    News & Views
    Nature Reviews Nephrology
    Volume: 7, P: 250-251

  • The prevalence of cardiovascular disease is high in patients with chronic kidney disease (CKD), especially in those with end-stage renal disease. In this Review, Drüeke and Massy discuss the contribution of atherosclerosis to the development of cardiovascular disease in patients with CKD and describe data from clinical, imaging, morphological and experimental studies that provide evidence for atherogenesis as CKD progresses.

    • Tilman B. Drüeke
    • Ziad A. Massy
    Reviews
    Nature Reviews Nephrology
    Volume: 6, P: 723-735

  • This Review focuses on the role of drugs such as cinacalcet in the treatment of uremic secondary hyperparathyroidism. The authors present evidence to support their assertion that cinacalcet plus higher doses of calcium-based oral phosphate binders is a safe and efficacious alternative to currently recommended regimens. Other indications for calcimimetic drugs, such as predialysis secondary hyperparathyroidism and hypercalcemic hyperparathyroidism following kidney transplantation, are also discussed.

    • Irina Shahapuni
    • Matthieu Monge
    • Albert Fournier
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 2, P: 316-325

  • Since the latest K/DOQI guidelines were formulated, new data on drugs such as lanthanum carbonate and calcimimetics have become available. In light of this new information, Matthieu Monge and colleagues believe that current practice can be updated. In this Review, the authors outline their recommendations regarding drug selection, dosing regimens, and monitoring of hyperparathyroidism in dialysis patients.

    • Matthieu Monge
    • Irina Shahapuni
    • Albert Fournier
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 2, P: 326-336

  • A growing body of evidence indicates that monocytes, specifically intermediate (CD14++CD16+) monocytes, contribute to the development of atherogenesis and increase in number with worsening renal function. In this Review, Heine and colleagues on behalf of the EURECA-m working group of the ERA–EDTA, describe the developmental and functional characterization of monocyte subsets, with particular focus on prominent subsets in atherosclerosis and chronic kidney disease.

    • Gunnar H. Heine
    • Alberto Ortiz
    • Danilo Fliser
    Reviews
    Nature Reviews Nephrology
    Volume: 8, P: 362-369

  • Biomarkers have the potential to refine prognosis, improve risk stratification and guide therapy in patients on hemodialysis. The authors of this Review discuss the validation and potential use of biomarkers, including markers of chronic kidney disease-related mineral and bone disorders, markers of protein–energy wasting and inflammation, and markers of cardiovascular disease, in patients on hemodialysis. The authors also describe how proteomics can be used to identify and study new biomarkers.

    • Alberto Ortiz
    • Ziad A. Massy
    • Carmine Zoccali
    Reviews
    Nature Reviews Nephrology
    Volume: 8, P: 141-150

  • Hyperphosphataemia is associated with poor clinical outcomes but strong evidence that targeting serum phosphate improves these outcomes is lacking. Here the authors discuss the role, regulation and management of serum phosphate in chronic kidney disease, including the efficacies of phosphate binder therapy and dietary interventions.

    • Marc G. Vervloet
    • Siren Sezer
    • Denis Fouque
    Reviews
    Nature Reviews Nephrology
    Volume: 13, P: 27-38

  • Chronic kidney disease (CKD) affects numerous organs and systems, which in turn have effects on kidney function. This Review provides an overview of CKD as a systemic disease and discusses the multidirectional links between the kidney, bone, nervous and immune systems, and metabolism.

    • Carmine Zoccali
    • Raymond Vanholder
    • Gerard London
    Reviews
    Nature Reviews Nephrology
    Volume: 13, P: 344-358

  • The prevalence of cognitive dysfunction among people with chronic kidney disease (CKD) is disproportionately high compared with that in the general population. This Review examines current evidence on key drivers of cognitive impairment in people with CKD, and highlights gaps in knowledge and potential therapeutic targets.

    • Giovambattista Capasso
    • Casper F. M. Franssen
    • Robert J. Unwin
    Reviews
    Nature Reviews Nephrology
    Volume: 21, P: 536-552

  • Here, the authors review techniques for cardiovascular diagnosis, screening and monitoring in patients with CKD, including approaches to the diagnosis of cardiac ischaemia, left ventricular hypertrophy and dysfunction, arrhythmia, cerebrovascular disease, peripheral arterial disease, arterial stiffness and hypertension.

    • Carmine Zoccali
    • Patrick B. Mark
    • Andrzej Wiecek
    Reviews
    Nature Reviews Nephrology
    Volume: 19, P: 733-746

  • Chronic kidney disease (CKD) is the progressive, irreversible loss of renal function that has many causes and contributing factors. In this Primer, the authors describe the many consequences of CKD and how understanding — and treating — the underlying cause can substantially slow CKD progression.

    • Paola Romagnani
    • Giuseppe Remuzzi
    • Hans-Joachim Anders
    Reviews
    Nature Reviews Disease Primers
    Volume: 3, P: 1-24

  • This Review focuses on the epidemiology, pathogenesis and treatment of dyslipidaemia in patients with chronic kidney disease (CKD) and end-stage renal disease. The authors discuss emerging clinical data on the use of novel lipid-lowering agents and reappraise the 2013 KDIGO Guidelines for Lipid Management in CKD.

    • Charles J. Ferro
    • Patrick B. Mark
    • Carmine Zoccali
    Reviews
    Nature Reviews Nephrology
    Volume: 14, P: 727-749